Bystro.io

Bystro AI is an AI-native biomedical research platform designed to make large-scale genomic data searchable, interpretable, and actionable through natural language. Combining a high-performance annotation engine (DASH) with an agentic AI system (THiNK), the platform enables researchers and clinicians to analyse terabyte- to petabyte-scale genetic datasets without programming expertise. It functions as a “search engine for the genome,” allowing users to ask questions in plain language and receive verified, data-driven insights. Built on structured scientific data rather than probabilistic text generation, Bystro AI supports precision medicine, accelerates research workflows, and removes technical barriers in genomics and life sciences.

Bystro AI was founded by Dr. Alex Kotlar, a geneticist and bioinformatics expert whose work spans genetics, artificial intelligence, and large-scale computing. His motivation originated from personal experiences, including exposure to increased cancer risk following the Chernobyl disaster and a broader desire to make complex scientific tools accessible to all researchers.

During his PhD in genetics, Kotlar identified a major bottleneck in biomedical research: the inability of scientists to efficiently analyse massive genomic datasets due to technical complexity. Existing tools required deep expertise in programming, statistics, and bioinformatics, making advanced research inaccessible to many clinicians and researchers.

To address this, Kotlar developed a next-generation genomic annotation system that could process billions of genetic variants rapidly and integrate extensive biological knowledge. This evolved into Bystro’s core engine, which became the fastest and most scalable variant annotation system globally.

Building on this foundation, he introduced a natural-language search layer, enabling users to query genetic data in plain English rather than code. This innovation marked a shift from traditional bioinformatics workflows to intuitive, search-driven analysis.

The platform later expanded into an AI-native system with the introduction of DASH (data annotation and dashboard layer) and THiNK (agentic AI reasoning system). Together, these components allow users not only to search genomic data but also to run complex analyses such as GWAS, clustering, and survival analysis directly within a conversational interface.

Today, Bystro AI is used by major academic institutions, including Emory University, and is positioned as a foundational platform for precision medicine and large-scale genomic research.

The mission of Bystro AI is to accelerate biomedical discovery and improve healthcare outcomes by combining structured scientific data with agentic artificial intelligence. It focuses on enabling scalable, reproducible, and verifiable genomic analysis while ensuring that insights are grounded in real data rather than probabilistic outputs. By doing so, Bystro aims to support faster research cycles, enhance clinical decision-making, and advance precision medicine globally.

Bystro AI aims to make personalised medicine universally accessible by transforming complex genomic data into intuitive, language-driven interactions. Its vision is to eliminate technical barriers in life sciences and enable any researcher, clinician, or organisation to derive meaningful insights from biological data quickly and accurately. The platform seeks to redefine how humans interact with scientific data by making natural language the primary interface for research and discovery.

Bystro AI and its founder have received recognition within academic and scientific communities for advancing genomic data analysis. The platform has been adopted by leading research institutions, including Emory University, where it supports large-scale genomic studies and clinical applications.

The platform itself has been recognised for achieving high standards of reliability required for academic research and for introducing a novel approach to combining natural language interfaces with large-scale biological data analysis.

Bystro.io offers an integrated suite of AI-powered tools designed to simplify genomic analysis and make precision medicine accessible at scale. Its platform combines high-performance data infrastructure with agentic artificial intelligence, enabling users to move from raw genetic data to actionable insights through a natural language interface.

At the core of Bystro’s offering is its genomic annotation and data layer, which processes large-scale datasets and enriches them with structured biological information. This system aggregates knowledge from multiple scientific databases and produces hundreds of annotation fields for each genetic variant, allowing researchers to analyse complex datasets with speed and reproducibility. The platform supports cohort-level analysis, enabling studies across thousands of samples while maintaining traceability and version control.

Built on top of this foundation is Bystro’s agentic AI system, which translates natural language queries into executable scientific workflows. Rather than relying solely on probabilistic outputs, the system coordinates deterministic tools such as statistical analysis, clustering, and regression models. This allows users to perform tasks like genome-wide association studies (GWAS), variant filtering, and survival analysis directly within a conversational interface, while maintaining full transparency and verifiability of results.

Bystro also provides personalised genomics services for individuals and clinicians. Users can upload raw genetic data from platforms such as 23andMe or AncestryDNA and explore insights related to health risks, drug response, and lifestyle optimisation. The system enables users to investigate genetic links to specific conditions, understand pharmacogenomic implications, and generate evidence-based reports backed by scientific literature.

For enterprise and research applications, Bystro offers biotech and clinical research solutions, particularly in areas such as clinical trial design and cohort stratification. The platform can identify genetic subtypes within patient populations, predict treatment response, and optimise inclusion criteria for targeted therapies. This capability significantly reduces the time and cost associated with large-scale genomic studies, compressing analyses that traditionally required weeks or months into minutes.

Additionally, Bystro supports predictive healthcare and precision medicine workflows by shifting analysis upstream—from interpreting medical records to anticipating disease risk based on genomic data. Its tools enable early detection of potential conditions, personalised treatment planning, and long-term health monitoring, positioning the platform as a bridge between research-grade genomics and real-world clinical application.